Nanobiotix S.A. (ENXTPA: NANO)
Health Care · Biotechnology · FR
€38.04
+1.71% today · +351.8% 1Y
Nanobiotix S.A. (ENXTPA: NANO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.25B and employs 100 people.
Over the last twelve months the share price has gained 351.8%, trading between 6.96 and 47.66.
Tweenvest scores Nanobiotix S.A. across four factors: quality 24/100, value 64/100. Its strongest factor is value.
NANO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.25B
- Revenue (TTM)
- $38.27M
- P/E
- —
- EPS
- -0.50
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- €47.66
- 52-week low
- €6.96
- Avg volume (3M)
- —
- Shares outstanding
- 50.71M
- Employees
- 100
- Next earnings
- —
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- ISIN
- FR0011341205
- Founded
- 2003
- Listed since
- Oct 29, 2012
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.31 | +0.51% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.